B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
BHVN
BiohavenANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
BHV7000-303 remains fully enrolled and on schedule, limiting the hold's immediate effect on the pivotal readout. Positive epilepsy data, reassuring metabolite work, and October BHV-1530 activity could restore confidence, while BHV-1300 has already entered pivotal development [#8-K-2026-09-10] [#SEC-8K-2026-08-10].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +25.9.
What can break
Additional nonclinical work may not resolve FDA concerns promptly, prolonging the BHV-7000 enrollment pause.
Momentum
72
Value
41
Sentiment
91
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $24.00 · Bear $7.00Analysis 2026-09-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $23.08
Why
Momentum72 · Δ7d +8.3
Value41 · Δ7d -0.0
Sentiment91 · Δ7d +25.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +25.9.
Contradictions & invalidation
- • Additional nonclinical work may not resolve FDA concerns promptly, prolonging the BHV-7000 enrollment pause.
- • Negative or equivocal BHV7000-303 efficacy, tolerability, or safety data could materially reduce pipeline value.
- • The partial clinical hold introduces a new safety and regulatory overhang for a priority program, pauses enrollment in BHV7000-302, and could impair the broader Kv7 platform if the metabolite finding proves relevant to humans.
Catalyst clock
2026-10-15
FDA partial-hold clarification
Lead driver: Sentiment · See AI snapshot
Momentum
72
9% active weight
Current posture
7d trendImproving
Δ7d
+8.3
Δ21d
+14.4
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
91
62% active weight
Current posture
7d trendImproving
Δ7d
+25.9
Δ21d
+11.9
Why this grade
Composite grade A. Momentum 72.2 / Value 41.2 / Sentiment 90.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-12. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.18B
Beta
3.56
Shares Out
151.04M
P/E (TTM) · Derived
-2.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.57
Rev YoY
-
EPS YoY
-52.9%
Gross Margin
-
Op Margin
-
Net Debt
-$35.3M
Current Ratio
4.73
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data